This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tsimihodimos, V. Articles by Elisaf, M. Search for Related Content PubMed Articles by Tsimihodimos, V. Articles by Elisaf, M. Social Bookmarking                         What's this?

Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values

Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Angeliki Kostoula, MD

Laboratory of Microbiology, University Hospital of Ioannina, Ioannina, Greece

Anna Kakafika, MD

Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Eleni Bairaktari, PhD

Laboratory of Biological Chemistry, Medical School, University of Ioannina, Ioannina, Greece

Alexandros D. Tselepis, MD, PhD

Laboratory of Biochemistry, School of Chemistry, University of Ioannina, Ioannina, Greece

Dimitri P. Mikhailidis, MD, FRSH, FACA, FRCPath

Department of Clinical Biochemistry, Royal Free and University College Medical School, University College (University of London), Royal Free Campus, London, United Kingdom

Moses Elisaf, MD, FRSH

Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Background: Atherosclerosis is the leading cause of death in developed countries. Although the mechanisms that underlie this process are not well defined, it has been proposed that atherosclerosis is mainly an inflammatory disease. In this context, a number of inflammatory markers have been studied for their ability to predict future cardiovascular events in asymptomatic individuals or patients with established atherosclerotic disease.

Methods and Results: The aim of our study was to evaluate the effect of micronized fenofibrate on serum inflammatory markers, such as C-reactive protein, fibrinogen, and plasma platelet-activating factor acetylhydrolase (PAF-AH) in patients with high triglyceride values. An analysis of baseline values revealed that hypertriglyceridemic patients (n = 58) exhibit an atherogenic phenotype, characterized not only by elevated lipid values but also by high concentrations of serum inflammatory markers. Along with the improvement in serum lipid profile (reduction in triglycerides and total cholesterol, low-density lipoprotein, and nonhigh-density lipoprotein-cholesterol, with a concomitant increase in high-density lipoprotein-cholesterol levels), fenofibrate administration significantly reduced the values of serum inflammatory markers by 34%, 9.5%, and 24.8% for C-reactive protein, fibrinogen, and plasma PAF-AH, respectively. However, with the exception of PAF-AH, these reductions in inflammatory markers were not correlated with the changes in lipid values.

Conclusions: In addition to its well-known hypolipidemic effects, fenofibrate may also possess significant anti-inflammatory properties that can contribute its antiatherogenic effect.

Key Words: hypertriglyceridemia • C-reactive protein • fibrinogen • PAF-AH

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 9, No. 1, 27-33 (2004)
DOI: 10.1177/107424840400900i105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. J. Robins, D. Collins, J. J. Nelson, H. E. Bloomfield, and B. F. Asztalos Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Cholesterol: The Veterans Affairs HDL Intervention Trial Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1172 - 1178. [Abstract] [Full Text] [PDF]

				T.-J. Wu, H.-Y. Ou, C.-W. Chou, S.-H. Hsiao, C.-Y. Lin, and P. C. Kao Decrease in Inflammatory Cardiovascular Risk Markers in Hyperlipidemic Diabetic Patients Treated with Fenofibrate Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 158 - 166. [Abstract] [Full Text] [PDF]

				A. Zalewski, J. J. Nelson, L. Hegg, and C. Macphee Lp-PLA2: A New Kid on the Block Clin. Chem., September 1, 2006; 52(9): 1645 - 1650. [Abstract] [Full Text] [PDF]

				C. M. Ballantyne, R. C. Hoogeveen, H. Bang, J. Coresh, A. R. Folsom, L. E. Chambless, M. Myerson, K. K. Wu, A. R. Sharrett, and E. Boerwinkle Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study Arch Intern Med, November 28, 2005; 165(21): 2479 - 2484. [Abstract] [Full Text] [PDF]

				T. Gerasimidis, G. Sfyroeras, G. Trellopoulos, L. Skoura, K. Papazoglou, K. Konstantinidis, D. Karamanos, A. Filaktou, and E. Parapanisiou Impact of Endograft Material on the Inflammatory Response After Elective Endovascular Abdominal Aortic Aneurysm Repair Angiology, November 1, 2005; 56(6): 743 - 753. [Abstract] [PDF]

				N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis Matrix Metalloproteinases and Diabetic Vascular Complications Angiology, March 1, 2005; 56(2): 173 - 189. [Abstract] [PDF]